GLP-1 Receptor Agonist (GLP-1 RA)

Deep dive

GLP-1 Receptor Agonist (GLP-1 RA): complete reference

A GLP-1 receptor agonist is a pharmaceutical agent that binds and activates the GLP-1 receptor (a G-protein-coupled receptor expressed on pancreatic beta cells, gastric smooth muscle, vagal nerves, and multiple brain regions). Unlike native GLP-1 (which is degraded within 1-2 minutes by DPP-4), these drugs are structurally modified to resist DPP-4 cleavage — through amino acid substitutions, fatty-acid acylation that promotes albumin binding (semaglutide, liraglutide), or fusion to an Fc domain (dulaglutide). The result is sustained receptor activation for hours to days, enabling daily dosing (Saxenda; Victoza and Byetta were discontinued in 2024), once-daily oral dosing (Rybelsus), or weekly dosing (Wegovy, Ozempic, Zepbound, Mounjaro, Trulicity; Bydureon BCise was discontinued in 2024). Tirzepatide additionally activates the GIP receptor — a dual mechanism that achieves greater weight loss in trials. The class first entered clinical use with exenatide (Byetta) in 2005 for type 2 diabetes; today GLP-1 agonists are FDA-approved for diabetes, chronic weight management, cardiovascular event reduction, and obstructive sleep apnea, depending on the specific drug.

In practice

When you take Wegovy, the semaglutide molecule binds to the same receptors your natural GLP-1 would activate — but unlike your body's GLP-1 (which lasts minutes), Wegovy stays active for about a week.

Clinical context

Different GLP-1 receptor agonists have different FDA-approved indications; clinicians select based on patient need (diabetes vs weight vs CVD) and tolerance.